Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Priestman

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|September 24, 1982
The present status of clinical studies with interferons in cancer in BritainT J Priestman
Cancer Treatment Reviews|December 1, 1979
Interferon: an anti-cancer agent?T J Priestman
Cancer Treatment Reviews|March 1, 1977
The place of radiotherapy in the management of rectal adenocarcinomaT J Priestman
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Early breast cancerT J Priestman
The Journal of Pathology|November 1, 1983
Interferons and cancer therapyT J Priestman
Journal of the Royal Society of Medicine|June 1, 1984
Quality of life after cytotoxic chemotherapy: discussion paperT J Priestman
The Canadian Journal of Oncology|February 1, 1996
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonistsT J Priestman
The Canadian Journal of Oncology|February 1, 1996
Palliative radiotherapy in the UKT J Priestman
Journal of the Royal Society of Medicine|March 1, 1978
Recent advances in cytotoxic therapy for gastrointestinal carcinoma: a reviewT J Priestman
Lancet (London, England)|July 19, 1980
Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant diseaseT J Priestman
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|September 24, 1982
The present status of clinical studies with interferons in cancer in BritainT J Priestman
Cancer Treatment Reviews|December 1, 1979
Interferon: an anti-cancer agent?T J Priestman
Cancer Treatment Reviews|March 1, 1977
The place of radiotherapy in the management of rectal adenocarcinomaT J Priestman
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Early breast cancerT J Priestman
The Journal of Pathology|November 1, 1983
Interferons and cancer therapyT J Priestman
Journal of the Royal Society of Medicine|June 1, 1984
Quality of life after cytotoxic chemotherapy: discussion paperT J Priestman
The Canadian Journal of Oncology|February 1, 1996
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonistsT J Priestman
The Canadian Journal of Oncology|February 1, 1996
Palliative radiotherapy in the UKT J Priestman
Journal of the Royal Society of Medicine|March 1, 1978
Recent advances in cytotoxic therapy for gastrointestinal carcinoma: a reviewT J Priestman
Lancet (London, England)|July 19, 1980
Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant diseaseT J Priestman
Pageof 6